NCT01798160已完成4 期
Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).
Johannes Gutenberg University Mainz0 个研究点目标入组 24 人开始时间: 2010年2月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 主要终点
- Progression-free-Survival
研究概览
简要总结
Selective Internal Radiation Therapy is superior to Transarterial Chemoembolisation for the treatment of intermediate stage hepatocellular carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years
- •HCC, proven by histology or according to EASL criteria
- •Intermediate stage HCC (stage B according to BCLC)
- •At least one measurable lesion in magnetic resonance imaging (MRI)
- •Tumor load ≤ 50%
- •preserved liver function (Child Pugh A and B)
排除标准
- •Patients feasible for curative treatment (e.g. resection or local ablation)
- •Previous TACE or SIRT
- •Chemotherapy during the last 4 weeks
- •Child Pugh stage C
- •BCLC stage D
- •ECOG Performance Status >0
- •Tumor involvement >50% of the liver
- •Extrahepatic tumor
- •Serum Bilirubin >2.0 mg/dl; Serum Albumin 2.8 g/dl, Serum Creatinine >2 mg/dl; Leukocytes <3000/ml; Thrombocytes <50000/ml
- •Clinically apparent ascites (ascites only in CT/MRI is no exclusion criteria)
- •Esophageal bleeding during the last 3 months
- •Hepatic encephalopathy
- •Transjugular intrahepatic portosystemic shunt (TIPS)
- •Infiltration or occlusion of the portal vein
- •Hepatofugal blood flow in the portal vein
- •Hepatopulmonary shunt ≥ 20% in the macroaggregated albumin scan
- •Contraindications against angiography
- •Gravidity
结局指标
主要结局
Progression-free-Survival
时间窗: up to three years
Overall-Survival
时间窗: up to three years
次要结局
未报告次要终点
研究者
Michael Bernhard Pitton
Consultant
Johannes Gutenberg University Mainz
相似试验
Unknown
2 期
Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).Intrahepatic Cholangiocellular CarcinomaNCT01798147Johannes Gutenberg University Mainz24
终止
2 期
SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic CholangiocarcinomaIntrahepatic CholangiocarcinomaNCT02807181Sirtex Medical89
Unknown
不适用
Comparison of SBRTand Repeat TACE for HCCHepatoCellular CarcinomaNCT03326375Gangneung Asan Hospital80
已完成
不适用
CIRSE Registry for SIR-Spheres in France (CIRT-FR)Liver CancerNCT03256994Cardiovascular and Interventional Radiological Society of Europe332
终止
3 期
Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to TransplantHCCHepatocellular CarcinomaNCT03960008Lahey Clinic9